Heart FailureREACTION-VADNCT07611188
REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices
A study testing Remote Physical Conditioning Program (Telerehabilitation) in people with Heart Failure and Advanced Heart Failure, run by Puerta de Hierro University Hospital at 10 sites in Spain.
Trial summary
Current international guidelines recommend that patients with a heart pump (left ventricular assist device, LVAD) participate in supervised exercise cardiac rehabilitation programs. However, not all patients with a heart pump are able to attend to a supervised program on a daily basis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device
- What is being tested?
- Remote Physical Conditioning Program (Telerehabilitation)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 78 participants
- Where
- 10 sitesSpain
- Study dates
- May 2026to Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Recent LVAD Implantation (<6 months)
- Clinical stability (defined as meeting all of the following criteria): discharge from the LVAD implantation hospitalization, absence of inotropic medication, hemoglobin >9 g/dL, and no active infection.
- Inability to participate in a supervised rehabilitation program (due to lack of availability, or inability because geographical reasons).
Who cannot join
- Functional Inability to Perform Cardiopulmonary Exercise Testing
- Prior Participation in a Supervised Rehabilitation Program (after the LVAD implantation)
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
Spain10 sites
Complejo Hospitalario Universitario de A Coruña
A Coruña, Galicia, 15006
Milena Antunez Ballesteros, MD, +34981178000, antbalmil@gmail.com
Hospital Clinic de Barcelona
Barcelona, Catalonia, 03036
María Sanz de la Garza, MD, PhD, +34932275400, sanz1@clinic.cat
Hospital Universitari de Bellvitge
Barcelona, Catalonia
Lorena Herrador Galindo, MD, +34932607500, lherradorgalindo@gmail.com
Hospital Ramon y Cajal
Madrid, Madrid, 28034
Carmen de Pablo Zarzosa, MD, PhD, +34913368000, cpablozarzosa@gmail.com
Hospital Clinico San Carlos
Madrid, Madrid, 28040
Josebe Goirigolzarri Artaza, MD, PhD, +34913303000, josebegoiri@gmail.com
Hospital 12 de Octubre
Madrid, Madrid, 28041
Maria Paz Sanz Ayan, MD, PhD, +34913908000, paz.sanz@salud.madrid.org
Hospital Puerta de Hierro
Majadahonda, Madrid, 28028
Mercedes Rivas-Lasarte, MD, PhD, +34911917843, rivaslasarte@gmail.com
Ramon Garrido Gonzalez, MD
Hospital Universitario de Salamanca
Salamanca, Castille and León, 37007
Complejo Hospitalario Universitario Santiago de Compostela
Santiago de Compostela, Galicia, 15706
Maria Ines Gomez Otero, MD, +34981950000, maria.ines.gomez.otero@sergas.es
Hospital Virgen del Rocío
Seville, Andalusia, 41013
Carlos Palacios Castelló, MD, +34955012000
About this study
Official title: Efficacy and Safety of a Remote Conditioning Program in Patients Supported With a Ventricular Assist Device: THE RE-ACTION-VAD TRIAL.
Current international guidelines recommend that patients with a heart pump (left ventricular assist device, LVAD) participate in supervised exercise cardiac rehabilitation programs. However, not all patients with a heart pump are able to attend to a supervised program on a daily basis.
The goal of this clinical trial is to determine whether a home-based exercise program helps patients with a heart pump improve their exercise capacity and quality of life, guided by telemedicine tools including a mobile app, smartwatch, and remote medical checkups. The study will also provide information about the safety of this program by monitoring for any issues or symptoms during home activity.
Read more
The trial aims to answer the following questions:
- Does a 12-week remote exercise program improve patients' exercise capacity? This will be measured using the 6-minute walk test and a cardiopulmonary exercise test.
- Is it safe for patients to follow this exercise plan at home while being monitored through a mobile app and smartwatch?
- Does the program improve quality of life and reduce feelings of anxiety or depression? This will be assessed using widely validated questionnaires, such as the Kansas City Cardiomyopathy Questionnaire.
Researchers will compare the remote exercise program to standard care, which usually does not include exercise for patients who are unable to attend the hospital daily.
Participants will:
- Join the study voluntarily after signing a consent form.
- Be randomly assigned, with a 50% chance of being in either the exercise group (following a structured plan with a mobile app) or the usual care group (receiving general written advice), to see which approach works best for recovery.
- Follow a 12-week home-based routine if in the exercise group, including warm-up routine, walking or cycling, respiratory exercises, and light strength training, all supported by the mobile app, smartwatch, and professional monitoring.
- Visit the hospital three times over six months for medical checkups, including walking and exercise tests, blood analyses, and questionnaires about physical and emotional health.
Read the detailed description
Introduction Although cardiac rehabilitation is recommended in patients with a durable Left Ventricular Assist Device (LVAD), approximately 50% of candidates cannot attend in-person programs due to geographical dificulties.
Study Rationale and Design The RE-ACTION-VAD Trial is the first multicenter randomized controlled trial designed to evaluate the efficacy and safety of a remote conditioning exercise program in patients with recent implantation of a durable Left Ventricular Assist Device (LVAD).
A total of 78 patients will be enrolled and randomized in a 1:1 ratio to:
- Remote conditioning group: patients will undergo a three-month home-based program including aerobic, resistance, and respiratory training. Follow-up will be conducted through Telemedicine (mobile application and a smart watch); or
- Usual care group: patients will receive written general exercise recommendations.
The primary objective is to assess whether there is an improvement in the distance covered on the 6-minute walk test at 6-month follow-up. Secondary objectives include evaluation of safety, and improvements in cardiopulmonary exercise parameters, quality of life questionnaires, frailty scales, and psychological questionnaires.
Intervention Logistics
The 12-week program is divided into an initial educational phase and a remote phase:
- Educational Phase (Week 1): Three in-person sessions to train patients on exercise execution, load management, and the use of respiratory devices.
- Remote Phase (Weeks 2-12): Individualized home routines including aerobic training, strength training, and respiratory.
Quality Assurance and Monitoring Plan
To ensure the integrity and standardization of the intervention across the 10 participating centers, the following quality measures are implemented:
- Site Monitoring: The study has contracted a Contract Research Organization (CRO), to perform clinical trial monitoring and auditing over a three-year period.
- Standardization of Procedures: Researchers from all centers are required to complete a rotation at the Hospital Ramón y Cajal Rehabilitation Unit to unify exercise protocols. Monthly supervision meetings are held to evaluate compliance and resolve clinical doubts.
Safety monitoring board: independent adverse event assessment blinded to the intervention group.
- Technical Validation: The mobile platform utilized for monitoring holds the requisite certifications, ensuring technical reliability and data security.
Data Management and Registry Procedures
- Data Entry and Validation: Data is captured using an electronic data capture system. The system includes predefined rules for data ranges and consistency to minimize entry errors.
- Source Data Verification (SDV): Investigators may cross-reference data from the electronic data capture system with hospital medical records to ensure accuracy, completeness, and representativeness.
- Data Dictionary: A comprehensive data dictionary is maintained within the study's electronic data management system, encompassing variables such as anthropometric measures, cardiopulmonary exercise test (CPET) parameters (VO₂ peak, VE/VCO₂, RER), 6-minute walk test (6MWT) distance, biomarkers (NT-proBNP, CA125), and validated quality-of-life scales (KCCQ, MLHFQ).
- Audit Trails: the electronic data capture system provides automated audit logs to track all data manipulations and user activity, ensuring full traceability.
Sample Size Assessment The study is powered to detect a clinically relevant difference of 35 meters in the 6MWT. Based on a standard deviation of 50 meters, an alpha of 0.05, and a power of 80%, 33 patients per group (66 total) are required. To account for an expected 15% dropout rate, the total sample size is set at 78 participants.
Statistical Analysis Plan (SAP) All analyses will follow the Intention-to-Treat (ITT) principle.
- Continuous Variables: Will be compared using the Student's T-test for independent samples or the Mann-Whitney U-test for non-parametric data.
- Categorical Variables: Will be analyzed using Chi-square or Fisher's Exact test.
- Missing Data Plan: While the ITT principle handles participants as randomized, the study also includes monthly supervision to incentivize compliance and minimize missing data.
- Significance: A p-value < 0.05 will be considered statistically significant.
Ethics and Confidentiality The protocol was approved by the Hospital Universitario Puerta de Hierro Ethics Committee (PI 143/25). Data is codified, and the link between codes and patient identity is stored in a password-protected offline file. Upon completion, anonymized data will be deposited in the Zenodo repository.
- Conditions
- Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device, LVAD, Cardiac Rehabilitation, Telemedicine
- Being tested
- Remote Physical Conditioning Program (Telerehabilitation), Usual care. No Remote Monitoring.
- Keywords
- Left Ventricular Assist Device, Advanced Heart Failure, Heart Failure, Cardiac Rehabilitation, Remote rehabilitation, Telemedicine, 6 minute walking test, Quality of Life, Cardiopulmonary Exercise Test, Telerehabilitation
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remote Physical Conditioning Program (Telerehabilitation)Other
The program includes structured warm-up routines, respiratory training, continuous aerobic exercise, and strength training, with remote follow-up conducted via telemedicine.
Usual care. No Remote Monitoring.Other
General Exercise Recommendations (Written Instructions). No Remote Monitoring.
| Study group | Role | What they receive |
|---|---|---|
| Remote Exercise Training Via Telemedicine | Experimental | Warm-up, Respiratory Training, Continuous Aerobic Exercise, and Strength Training. Remote Monitoring via Telemedicine. Receives: Other: Remote Physical Conditioning Program (Telerehabilitation) |
| Control Group | Other | Usual care. General Exercise Recommendations (Written Instructions). No Remote Monitoring. Receives: Other: Usual care. No Remote Monitoring. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Six-Minute Walk Test (6MWT)
Difference in walking distance (meters) in the Six-Minute Walk Test (6MWT).
Measured: 3 months
Secondary outcomes (17)
Program Safety
Evaluate program safety: composite of device alarms, driveline infections, device-related thromboembolic or hemorrhagic complications, cardiovascular events, ventricular arrhythmias, and heart failure decompensations.
Measured: 6 months
Cardiopulmonary Exercise Test (CPET): peak oxygen consumption (VO₂peak)
Changes in peak oxygen consumption (VO₂peak measured in ml/kg/m2)
Measured: 3 months
Cardiopulmonary Exercise Test (CPET): VE/VO₂ slope
Changes in submaximal parameters: VE/VO₂ slope (dimensionless ratio)
Measured: 3 months
Cardiopulmonary Exercise Test (CPET): oxygen consumption at the first and second ventilatory thresholds
Changes in submaximal parameters: oxygen consumption at the first and second ventilatory thresholds (measured in ml/kg/min)
Measured: 3 months
Cardiopulmonary Exercise Test (CPET): ventilatory equivalents
Changes in submaximal parameters: ventilatory equivalents (measured in L/min)
Measured: 3 months
Cardiopulmonary Exercise Test (CPET): Oxygen Uptake Efficiency Score (OUES)
Changes in submaximal parameters: The oxygen uptake efficiency slope (OUES) was calculated from the linear relationship between VO₂ and log₁₀VE and is expressed in mL·min-¹/log(L·min-¹).
Measured: 3 months
Cardiopulmonary Exercise Test (CPET): Respiratory Exchange Ratio
Changes in submaximal parameters: Respiratory Exchange Ratio (RER). The respiratory exchange ratio (RER) was calculated as VCO₂/VO₂ and is reported as a unitless ratio.
Measured: 3 months
Cardiopulmonary Exercise Test (CPET): oscillatory patterns
Changes in submaximal parameters: oscillatory patterns (Yes/No)
Measured: 3 months
Quality of life (QoL): Kansas City Cardiomyopathy Questionnaire (KCCQ).
Changes in quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQ is scored from 0 to 100, with higher scores indicating better health status.
Measured: 3 months
Quality of life (QoL): Minnesota Living with Heart Failure Questionnaire (MLHFQ).
Changes in quality of life measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). MLHFQ is scored from 0 to 105, with lower scores indicating better quality of life.
Measured: 3 months
Frailty screening (FRAIL scale)
Frailty screening using the FRAIL scale. FRAIL is scored 0 to 5, with higher scores indicating greater frailty.
Measured: 3 months
Fried physical frailty phenotype
Frailty measured using the Fried Physical Frailty Phenotype. Fried is a score ranging from 0 to 5, with higher scores indicate greater frailty.
Measured: 3 months
Psychological changes: depression (Beck Depression Inventory-II).
Depression symptoms were evaluated by the Beck Depression Inventory-II (BDI-II). BDI-II yields a total score ranging from 0 to 63, with higher scores reflecting greater severity of depressive symptoms.
Measured: 3 months
Psychological changes: anxiety (HADS)
Anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale (HADS), specifically the anxiety subscale (HADS-A), which yields a score ranging from 0 to 21, with higher scores reflecting greater severity of anxiety.
Measured: 3 months
Psychological changes: caregiver burden (Zarit)
Changes in caregiver burden were evaluated using the Zarit Burden Interview (ZBI), which yields a total score ranging from 0 to 88, with higher scores reflecting greater perceived caregiver burden.
Measured: 3 months
Respiratory muscle strength
Respiratory muscle strength was assessed by measuring maximal inspiratory pressure (MIP) using a handheld device (RP Check, Sibelmed Diagnostics Ltd.). Maximal inspiratory pressure (MIP) is expressed in cmH₂O, with higher values indicating greater inspiratory muscle strength.
Measured: 3 months
Prior outcomes in a 6-mont follow-up
All previously described outcomes will be compared at 6 months after study initiation.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2026
- Study startMay 2026 (estimated)
- Primary completionDec 2029 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Multicenter, randomized, and controlled clinical trial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 78 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Puerta de Hierro University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Carlos III Health Institute
- Responsible party
- Principal investigator, Mercedes Rivas-Lasarte, Puerta de Hierro University Hospital
- Investigators
- Mercedes Rivas-Lasarte, MD, PhD, Principal investigator, Hospital Puerta de Hierro, Madrid (Spain)Ramon Garrido Gonzalez, MD, Principal investigator, Hospital Puerta de Hierro, Madrid (Spain)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07611188
- Sponsor's protocol ID
- PI 143/25
- Other IDs
- PI25/00394
- Acronym
- REACTION-VAD
- Status last verified
- May 2026
- First submitted
- 6 Mar 2026
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Upon completion of the project and publication of the primary analysis, the data will be deposited in the Zenodo repository following appropriate anonymization procedures. The dataset will be accompanied by metadata in Zenodo including: (1) data provenance, (2) patient population characteristics, and (3) a detailed description of the study variables. Access to data stored in the internal repository for other investigators with legitimate scientific interest will be subject to approval by the Ethics Committee. This approach ensures compliance with open-access data requirements applicable to publicly funded research projects, while maintaining data within a controlled environment consistent with their nature as personal data.
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of a Remote Conditioning Program in Patients Supported With a Ventricular Assist Device: THE RE-ACTION-VAD TRIAL.
- ClinicalTrials.gov ID
- NCT07611188
- Acronym / sponsor ID
- REACTION-VAD / PI 143/25
- Conditions
- Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device, LVAD, Cardiac Rehabilitation, Telemedicine
- Keywords
- Left Ventricular Assist Device, Advanced Heart Failure, Heart Failure, Cardiac Rehabilitation, Remote rehabilitation, Telemedicine, 6 minute walking test, Quality of Life
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 78 participants (estimated)
- Lead sponsor
- Puerta de Hierro University HospitalUniversity, hospital or other
- Collaborators
- Carlos III Health Institute
- Study start
- May 2026 (estimated)
- Primary completion
- Dec 2029 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 28 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Current international guidelines recommend that patients with a heart pump (left ventricular assist device, LVAD) participate in supervised exercise cardiac rehabilitation programs. However, not all patients with a heart pump are able to attend to a supervised program on a daily basis.
The goal of this clinical trial is to determine whether a home-based exercise program helps patients with a heart pump improve their exercise capacity and quality of life, guided by telemedicine tools including a mobile app, smartwatch, and remote medical checkups. The study will also provide information about the safety of this program by monitoring for any issues or symptoms during home activity.
The trial aims to answer the following questions:
- Does a 12-week remote exercise program improve patients' exercise capacity? This will be measured using the 6-minute walk test and a cardiopulmonary exercise test.
- Is it safe for patients to follow this exercise plan at home while being monitored through a mobile app and smartwatch?
- Does the program improve quality of life and reduce feelings of anxiety or depression? This will be assessed using widely validated questionnaires, such as the Kansas City Cardiomyopathy Questionnaire.
Researchers will compare the remote exercise program to standard care, which usually does not include exercise for patients who are unable to attend the hospital daily.
Participants will:
- Join the study voluntarily after signing a consent form.
- Be randomly assigned, with a 50% chance of being in either the exercise group (following a structured plan with a mobile app) or the usual care group (receiving general written advice), to see which approach works best for recovery.
- Follow a 12-week home-based routine if in the exercise group, including warm-up routine, walking or cycling, respiratory exercises, and light strength training, all supported by the mobile app, smartwatch, and professional monitoring.
- Visit the hospital three times over six months for medical checkups, including walking and exercise tests, blood analyses, and questionnaires about physical and emotional health.
Detailed description
Introduction Although cardiac rehabilitation is recommended in patients with a durable Left Ventricular Assist Device (LVAD), approximately 50% of candidates cannot attend in-person programs due to geographical dificulties.
Study Rationale and Design The RE-ACTION-VAD Trial is the first multicenter randomized controlled trial designed to evaluate the efficacy and safety of a remote conditioning exercise program in patients with recent implantation of a durable Left Ventricular Assist Device (LVAD).
A total of 78 patients will be enrolled and randomized in a 1:1 ratio to:
- Remote conditioning group: patients will undergo a three-month home-based program including aerobic, resistance, and respiratory training. Follow-up will be conducted through Telemedicine (mobile application and a smart watch); or
- Usual care group: patients will receive written general exercise recommendations.
The primary objective is to assess whether there is an improvement in the distance covered on the 6-minute walk test at 6-month follow-up. Secondary objectives include evaluation of safety, and improvements in cardiopulmonary exercise parameters, quality of life questionnaires, frailty scales, and psychological questionnaires.
Intervention Logistics
The 12-week program is divided into an initial educational phase and a remote phase:
- Educational Phase (Week 1): Three in-person sessions to train patients on exercise execution, load management, and the use of respiratory devices.
- Remote Phase (Weeks 2-12): Individualized home routines including aerobic training, strength training, and respiratory.
Quality Assurance and Monitoring Plan
To ensure the integrity and standardization of the intervention across the 10 participating centers, the following quality measures are implemented:
- Site Monitoring: The study has contracted a Contract Research Organization (CRO), to perform clinical trial monitoring and auditing over a three-year period.
- Standardization of Procedures: Researchers from all centers are required to complete a rotation at the Hospital Ramón y Cajal Rehabilitation Unit to unify exercise protocols. Monthly supervision meetings are held to evaluate compliance and resolve clinical doubts.
Safety monitoring board: independent adverse event assessment blinded to the intervention group.
- Technical Validation: The mobile platform utilized for monitoring holds the requisite certifications, ensuring technical reliability and data security.
Data Management and Registry Procedures
- Data Entry and Validation: Data is captured using an electronic data capture system. The system includes predefined rules for data ranges and consistency to minimize entry errors.
- Source Data Verification (SDV): Investigators may cross-reference data from the electronic data capture system with hospital medical records to ensure accuracy, completeness, and representativeness.
- Data Dictionary: A comprehensive data dictionary is maintained within the study's electronic data management system, encompassing variables such as anthropometric measures, cardiopulmonary exercise test (CPET) parameters (VO₂ peak, VE/VCO₂, RER), 6-minute walk test (6MWT) distance, biomarkers (NT-proBNP, CA125), and validated quality-of-life scales (KCCQ, MLHFQ).
- Audit Trails: the electronic data capture system provides automated audit logs to track all data manipulations and user activity, ensuring full traceability.
Sample Size Assessment The study is powered to detect a clinically relevant difference of 35 meters in the 6MWT. Based on a standard deviation of 50 meters, an alpha of 0.05, and a power of 80%, 33 patients per group (66 total) are required. To account for an expected 15% dropout rate, the total sample size is set at 78 participants.
Statistical Analysis Plan (SAP) All analyses will follow the Intention-to-Treat (ITT) principle.
- Continuous Variables: Will be compared using the Student's T-test for independent samples or the Mann-Whitney U-test for non-parametric data.
- Categorical Variables: Will be analyzed using Chi-square or Fisher's Exact test.
- Missing Data Plan: While the ITT principle handles participants as randomized, the study also includes monthly supervision to incentivize compliance and minimize missing data.
- Significance: A p-value < 0.05 will be considered statistically significant.
Ethics and Confidentiality The protocol was approved by the Hospital Universitario Puerta de Hierro Ethics Committee (PI 143/25). Data is codified, and the link between codes and patient identity is stored in a password-protected offline file. Upon completion, anonymized data will be deposited in the Zenodo repository.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Multicenter, randomized, and controlled clinical trial
| Arm | Type | Receives |
|---|---|---|
| Remote Exercise Training Via Telemedicine | Experimental | Other: Remote Physical Conditioning Program (Telerehabilitation)Warm-up, Respiratory Training, Continuous Aerobic Exercise, and Strength Training. Remote Monitoring via Telemedicine. |
| Control Group | Other | Other: Usual care. No Remote Monitoring.Usual care. General Exercise Recommendations (Written Instructions). No Remote Monitoring. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Recent LVAD Implantation (<6 months)
- Clinical stability (defined as meeting all of the following criteria): discharge from the LVAD implantation hospitalization, absence of inotropic medication, hemoglobin >9 g/dL, and no active infection.
- Inability to participate in a supervised rehabilitation program (due to lack of availability, or inability because geographical reasons).
Key exclusion criteria (2 listed)
- Functional Inability to Perform Cardiopulmonary Exercise Testing
- Prior Participation in a Supervised Rehabilitation Program (after the LVAD implantation)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remote Physical Conditioning Program (Telerehabilitation)The program includes structured warm-up routines, respiratory training, continuous aerobic exercise, and strength training, with remote follow-up conducted via telemedicine. | Other | Remote Exercise Training Via Telemedicine |
| Usual care. No Remote Monitoring.General Exercise Recommendations (Written Instructions). No Remote Monitoring. | Other | Control Group |
Primary outcome
Six-Minute Walk Test (6MWT)
Time frame: 3 months
Difference in walking distance (meters) in the Six-Minute Walk Test (6MWT).
17 secondary outcomes
Program Safety
Time frame: 6 months
Cardiopulmonary Exercise Test (CPET): peak oxygen consumption (VO₂peak)
Time frame: 3 months
Cardiopulmonary Exercise Test (CPET): VE/VO₂ slope
Time frame: 3 months
Cardiopulmonary Exercise Test (CPET): oxygen consumption at the first and second ventilatory thresholds
Time frame: 3 months
Cardiopulmonary Exercise Test (CPET): ventilatory equivalents
Time frame: 3 months
Cardiopulmonary Exercise Test (CPET): Oxygen Uptake Efficiency Score (OUES)
Time frame: 3 months
Cardiopulmonary Exercise Test (CPET): Respiratory Exchange Ratio
Time frame: 3 months
Cardiopulmonary Exercise Test (CPET): oscillatory patterns
Time frame: 3 months
Quality of life (QoL): Kansas City Cardiomyopathy Questionnaire (KCCQ).
Time frame: 3 months
Quality of life (QoL): Minnesota Living with Heart Failure Questionnaire (MLHFQ).
Time frame: 3 months
Frailty screening (FRAIL scale)
Time frame: 3 months
Fried physical frailty phenotype
Time frame: 3 months
Psychological changes: depression (Beck Depression Inventory-II).
Time frame: 3 months
Psychological changes: anxiety (HADS)
Time frame: 3 months
Psychological changes: caregiver burden (Zarit)
Time frame: 3 months
Respiratory muscle strength
Time frame: 3 months
Prior outcomes in a 6-mont follow-up
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Individual participant dataSharing planned: Yes. Upon completion of the project and publication of the primary analysis, the data will be deposited in the Zenodo repository following appropriate anonymization procedures. The dataset will be accompanied by metadata in Zenodo including: (1) data provenance, (2) patient population characteristics, and (3) a detailed description of the study variables. Access to data stored in the internal repository for other investigators with legitimate scientific interest will be subject to approval by the Ethics Committee. This approach ensures compliance with open-access data requirements applicable to publicly funded research projects, while maintaining data within a controlled environment consistent with their nature as personal data.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mercedes Rivas-Lasarte, MD, PhD principal investigator
Hospital Puerta de Hierro, Madrid (Spain)
Ramon Garrido Gonzalez, MD principal investigator
Hospital Puerta de Hierro, Madrid (Spain)
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remote Physical Conditioning Program (Telerehabilitation) in people with Heart Failure and Advanced Heart Failure, run by Puerta de Hierro University Hospital at 10 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mercedes Rivas-Lasarte, MD, PhD, Cardiologist (+34911917843, rivaslasarte@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Six-Minute Walk Test (6MWT) (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.